EQT's Actavis still in the race for for ratiopharm

Competing strategic buyers are Teva and and Pfitzer. Originally, the company was to be sold for between EUR 2bn and EUR 2.5bn, but sources suggest the company could fetch as much as EUR 3bn.

Ratiopharm is being sold to lighten the debt load of the industrial empire of late Adolf Merckle. Private equity firms that submitted bids in the first round were TPG, Advent in a consortium with Goldman Sachs, Permina, KKR and EQT.

The ratiopharm group is a generic drugs manufacturer with a total turnover of €1.7bn in 2008. The company consists partly of independently operating enterprises such as the smaller-scale generic producer CT Arzneimittel, or the Canadian Technilab group that was acquired in 2000. The vendor plans to sell the group as one, but may also consider selling the assets separately.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Germany
• EQT
• Large-cap buyout